HOME > ARCHIVE
ARCHIVE
- Mylan Enters Market in Japan by Acquiring Merck's Generic Drug Business
October 15, 2007
- Public Opinions Invited on Documents Required for Applications for Generics
October 15, 2007
- Mitsubishi Tanabe Pharma Corp. Aims at Becoming Global Drug Discovery Company
October 15, 2007
- Kaken Completes PIIb Trial for KCB-1D as Drug to Regenerate Periodontal Tissue
October 15, 2007
- Taisho Licenses Psychiatric Drug Candidates to BrainCells
October 15, 2007
- Silodosin Was Found to Be Superior to Tamsulosin: Kissei
October 15, 2007
- EPS Ties Up with Medidata Solutions Regarding EDC Software
October 15, 2007
- First Gene Therapeutic to Regenerate Blood Vessels Expected in 2008
October 15, 2007
- VITAL-NET, KSK Enter into Comprehensive Business Alliance
October 15, 2007
- Physician-Initiated Trials Led by JMACCT Generating Results
October 15, 2007
- Council Recommends Improvements of Drug Trade Practices
October 15, 2007
- Guideline Issued on Multinational Cooperative Clinical Studies
October 15, 2007
- JMA Does Not Support NHI Pricing System Proposed by Industry
October 8, 2007
- JT, Torii License New Drug for Hyperphosphatemia from Keryx
October 8, 2007
- GSK Applies for Cervical Cancer Vaccine
October 8, 2007
- Wyeth Applies for the Pneumococcus Vaccine Prevenar
October 8, 2007
- Yasuo Fukuda Elected Prime Minister
October 8, 2007
- BUSINESS NEWS IN BRIEF
October 8, 2007
- Japan Should Switch to Mixed Vaccines: Dr Kamiya
October 8, 2007
- SSRIs Effective against Post-stroke Depression: Pfizer Seminar
October 8, 2007
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
